1513 related articles for article (PubMed ID: 18036391)
1. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
2. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
4. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
6. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
7. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
[TBL] [Abstract][Full Text] [Related]
8. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
10. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
11. Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.
Cheen HH; Lim SH; Huang MC; Bee YM; Wee HL
Clin Ther; 2014 Jul; 36(7):1043-53. PubMed ID: 24913030
[TBL] [Abstract][Full Text] [Related]
12. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
Asche CV; Luo W; Aagren M
Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
Buysman E; Conner C; Aagren M; Bouchard J; Liu F
Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
[TBL] [Abstract][Full Text] [Related]
14. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
15. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe.
Lee LJ; Li Q; Reynolds MW; Pawaskar MD; Corrigan SM
J Med Econ; 2011; 14(1):75-86. PubMed ID: 21231863
[TBL] [Abstract][Full Text] [Related]
16. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
17. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
[TBL] [Abstract][Full Text] [Related]
18. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
19. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
Davis SN; Wei W; Garg S
Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
